Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis

• Status: Unknown status
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a limited duration of treatment (two weeks of low molecular weight treatment) is a safe and effective treatment for distal deep vein thrombosis of the lower limb.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Monash Medical Centre
• Collaborators: Auckland City Hospital; Christchurch Hospital, NZ; Eastern Health, Victoria; Middlemore Hospital, New Zealand; North Shore Hospital, New Zealand; Prince of Wales Hospital, Sydney; Royal Adelaide Hospital, Adelaide; Southern Health, Victoria
• Treatments: Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• Patients aged 18 years or older with acute symptomatic provoked or unprovoked distal vein thrombosis (axial or muscular veins but not involving trifurcation or distal popliteal vein)

• Absence of symptomatic pulmonary embolism

Exclusion Criteria:

• DVT involving trifurcation or more proximal leg veins on imaging

• Prior DVT

• Active malignancy ie present at time of diagnosis, or on treatment, or treatment completed within 3 months

• Ongoing risk factors for propagation e.g. immobility (>50% of day in bed or ≥72 hours), plaster cast or non-weight bearing

• Other indication for therapeutic anticoagulation (e.g. AF)

• Active gastro-oesophageal ulceration or bleeding

• Other high risk for bleeding (e.g. recent neurosurgery, vascular retinopathy, coagulopathy)

• Platelet count <80 x 109/L

• Renal impairment (CrCl <30ml/min) • Pregnancy or lactation